Key Highlights
● Kodiak Sciences (KOD) closed at $89.92 on Monday, up about 178%, after Zenkuda data on longer dosing intervals.
● The company reported that 54% of Zenkuda patients were on a 24-week interval at year one under strict retreatment criteria.
● Fewer injections could ease the burden on older wet AMD patients, caregivers and busy retina clinics, though uptake remains unproven.
● The shares opened near $61.71 against a Friday close of $32.35, so most of the gain arrived at the open.
For many older people with wet age-related macular degeneration, treatment means repeated injections into the eye. That is why one detail from Kodiak Sciences (NASDAQ:KOD) mattered so much on Monday, September 28: the company reported that 54% of patients on its drug Zenkuda were on a six-month dosing interval at the one-year mark. The stock closed at $89.92, up about 178% from $32.35 on Friday.
The Data Behind the Move
The pivotal Phase 3 DAYBREAK trial compared two Kodiak drugs, Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501), with aflibercept. Both met their primary vision endpoints, according to the company. The dosing result for Zenkuda used a strict treat-to-dryness approach, in which the next injection is timed to signs of fluid in the retina rather than a fixed calendar. For tabirafusp-ted, the company said dosing was fixed at eight weeks with additional doses as needed.
The company also reported no intraocular inflammation with Zenkuda, a safety issue that has weighed on some eye drugs. Kodiak's chief medical officer said the drug's profile has come into focus after four years of development and matched what the company designed the drug to deliver, with rapid disease control and the potential for six-month durability.
Why Fewer Injections Matter
Each injection means a clinic visit, and many patients rely on family members to get there. Longer gaps mean less discomfort and less strain on retina clinics. Investors also know that comparing dosing intervals across trials is difficult, so the market will look for fuller data. Regulators will judge the evidence, and rivals already sell established treatments, so the road from trial data to a launched product is long.
A Gap Open and a Wide Range
According to market data, the shares opened near $61.71, touched a high of $95.77 and closed at $89.92, so most of the gain arrived at the open. The session ended with the S&P 500 down 59.72 points at 7,683.69, the Dow down 347.11 points at 51,481.51 and the Nasdaq Composite down 248.34 points at 26,820.38, with eight of the 11 S&P 500 sectors lower. Energy costs added to the strain. Crude rose after President Trump rejected Iran's plan to reopen the Strait of Hormuz, leaving Brent near $105.28 a barrel.
What to Watch for Kodiak Sciences
Kodiak plans a multi-indication Biologics License Application for Zenkuda in the fourth quarter of 2026, and fuller DAYBREAK results should follow at medical meetings. A market summary put Kodiak's Liquidity at roughly $126 million at mid-year, so financing plans may also draw attention after a rise this large.
Long-dated Treasury yields kept climbing. The 10-year reached its highest since 2007 and the 30-year its highest since 2004, tightening financial conditions for companies that rely on borrowed money. The week ahead includes JOLTS and consumer confidence on Tuesday, PCE Inflation on Wednesday, ISM Manufacturing on Thursday and the September jobs report on Friday, each of which could move yields.






Please wait processing your request...